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Abstract
Objective: To investigate the direct and indirect costs of uterine fibroid (UF) surgery.
Methods: Data were obtained from the MarketScan Commercial Claims and Encounters databases for 1999–2004.
Our sample included 22,860 women with insurance coverage who were treated surgically for UF and 14,214
women who were treated nonsurgically for UF. Medical care costs and missed workdays were divided into
baseline (1 year prior to surgery) and postoperative (1 year after surgery) periods. For a subsample of women,
we calculated average annual costs 3 years before and after their surgery.
Results: Of patients electing surgery, 85.9% underwent hysterectomy, 7.6% myomectomy, 4.9% endometrial
ablation, and 1.6% uterine artery embolization (UAE). Women undergoing UAE incurred the highest medical
care costs in the operative year ($16,430 unadjusted, $20,634 adjusted for confounders), followed by hysterec-
tomy ($15,180 unadjusted, $17,390 adjusted), myomectomy ($14,726 unadjusted, $18,674 adjusted), and endo-
metrial ablation ($12,096 unadjusted, $13,019 adjusted). Women treated nonsurgically incurred costs of $7,460
unadjusted and $8,257 adjusted during the year after they were diagnosed with UF. Three years after surgery,
patients treated with hysterectomy had the lowest annual costs. Missed workdays in the year after surgery
were high, resulting in significant losses to employers in the magnitude of $6,670–$25,229, depending on treat-
ment, values assigned to missed workdays, and whether the analyses adjusted for confounders.
Conclusions: UF surgical treatment costs were high. Absenteeism and disability were important components
of the cost burden of UF treatment for women, their employers, and the healthcare system.
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Introduction
UTERINE FIBROIDS (UF), benign tumors of the uterus, arecommon and sometimes debilitating growths that affect
women during their prime reproductive and work years. Ul-
trasound evidence indicates that 70% of white women and
80% of African American women may have UF by age 50.1
Symptoms of UF include abnormal bleeding, pain, pressure,
and anemia.2–4 Most women with UF will not experience
these symptoms or will seek only over-the-counter (OTC)
remedies; however, in any given year, about 1% of child-
bearing-aged women in the United States will seek treatment
for UF.5
Fibroid symptoms may be managed with medical thera-
pies, such as non-steroidal anti-inflammatory drugs (NSAIDS)
and hormone therapy (HT), or may be alleviated by surgi-
cal procedures.6,7 The most common surgical procedures for
UF are hysterectomy and myomectomy. UF is the most com-
mon reason for the roughly 600,000 hysterectomies provided
each year in the United States.8 Newer and less common
treatments for UF include uterine artery embolization (UAE),
which shrinks the fibroid by blocking blood flow, and en-
dometrial ablation, which uses lasers and electric current to
destroy part of the uterine lining.9,10
Few previous studies have addressed the cost of surgical
treatments for UF. A recent review by Mauskopf et al.11
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found four studies that reported the direct cost of medical
care for UF treatments. Two of these studies (Myers et al.12
and Baker et al.13) were based on hospital charges from a
single institution, and three used hospital charges that were
converted to costs using a charge/cost ratio. Myers et al.12
studied hysterectomy and myomectomy, but their study did
not include professional fees. Baker et al.13 reported only hos-
pital charges for myomectomy. The third study identified by
Mauskopf et al.11 used hospital charges from the Healthcare
Cost and Utilization Project’s Nationwide Inpatient Sample
to report on myomectomy and hysterectomy charges (Zhao
et al.14). The fourth study, by Subramanian et al.,15 consid-
ered only myomectomy and included inpatient and outpa-
tient myomectomy in a population of privately insured
women.
Mauskopf et al.11 found no studies that reported the costs
of endometrial ablation, nor did they find any studies that
included the indirect costs of treatment resulting from
missed workdays by UF patients. A recent study by Hart-
mann et al.16 found that women with UF were three times
as likely as women without UF to have disability claims, cost-
ing about $771 per patient per year (in 2003 dollars).
There is limited research on long-term outcomes from pro-
cedures to alleviate the symptoms of UF. Myers et al.7 sum-
marized results from 24 studies of myomectomy and found
that 4%–12% of laparoscopic or abdominal myomectomy pa-
tients had subsequent conservative surgical procedures.
Variation in reported rates of subsequent conservative sur-
gical therapy was greatest for hysteroscopic myomectomy
patients (3%–76% of patients had subsequent therapy). The
incidence of hysterectomy to treat recurrence of symptoms
for patients who previously had a myomectomy ranged from
0.5% to 8.0%. Other research shows that most women expe-
rience significant improvements in symptoms 1–2 years af-
ter surgery.3,17,18
Our study fills some important knowledge gaps concern-
ing the cost implications of surgical treatment for UF. Pre-
vious studies have focused on perioperative costs (costs 
incurred around the time of the surgery). We study periop-
erative costs and also follow patients for 1–3 years after sur-
gery. We also assess productivity losses by measuring
missed workdays due to absenteeism and disability in the
year before and the year after surgery. Finally, we examine
costs for women with UF who did not receive surgery, be-
fore and after receiving a diagnosis for the disease, to pro-
vide context for expenditures associated with surgical treat-
ments.
Materials and Methods
Data sources and sample members
The data sources for this study were the Thomson Health-
care MarketScan Commercial Claims and Encounter (CCAE)
database for the years 1999–2004 and the MarketScan Health
and Productivity Management (HPM) database for the years
1999–2002. The CCAE database provided information on di-
agnoses, time and place of service, healthcare utilization, and
payments for healthcare services and prescription drugs for
women who were enrolled in employer-sponsored health
plans in the United States. The HPM database provided ad-
ditional information on the disability and absenteeism ex-
perience for the subset of women who were employed dur-
ing UF treatment and whose employers contributed those
data to Thomson Healthcare. 
Our sample included women aged 25–54 who had symp-
tomatic UF (i.e., those who received healthcare services to
treat UF). Sample members were continuously enrolled in
their employer-sponsored health plan(s) for at least 2 years
during the measurement period. To identify women with
clinically significant UF, we required all patients in the sam-
ple to have (1) at least one insurance claim with a UF diag-
nosis code (ICD-9-CM diagnosis codes 218.0–218.9 or
654.10–654.12) for an inpatient stay or an emergency room
visit or (2) at least two claims with a UF diagnosis code for
outpatient visits that were at least 30 days apart. We required
at least two outpatient claims with a UF diagnosis to rule out
coding errors (the second outpatient claim served as a con-
firmatory diagnosis).
Women with UF were assigned to five mutually exclusive
groups based on the type of treatment they received for their
UF symptoms. Four groups included patients treated surgi-
cally with either (1) hysterectomy, (2) myomectomy, (3)
UAE, or (4) endometrial ablation. The fifth group included
patients who were treated without surgery (i.e., by medical
management or watchful waiting). CPT-4 procedure codes
for each treatment category are shown in Table 1. Patients
with procedure codes from more than one surgical group
(e.g., where both myomectomy and endometrial ablation
CPT-4 codes were present) were excluded from the analysis
(55 patients).
Cost measures
In contrast to other studies that used hospital charges
data,12,13 we used actual payments to the provider to calcu-
late healthcare expenditures. Actual payments reflect the re-
ality of the marketplace and account for any negotiated dis-
counts, as well as the employer’s and patient’s share of costs.
Thus, payments from the insurer plus payments from the pa-
tient (including deductibles and copayments) were included
in the total payment measure. All payments were adjusted
to 2005 dollars using the Consumer Price Index (CPI).19
About 20% of the women in our sample were enrolled in
capitated plans. Detailed service-level payments were not
available for these patients. We, therefore, imputed pay-
ments for women in capitated plans using standard meth-
ods.20 Specifically, we matched encounters for women in
capitated plans with claims for similar women who were en-
rolled in fee-for-service (FFS) indemnity plans. This match-
ing was based on procedure code, the census region where
the patient lived, and the year of service. We then assigned
the payment on the FFS claim to the matching capitated
claim. 
To assess productivity-related losses, we calculated the
number of missed workdays due to absenteeism and dis-
ability for patients undergoing treatment. Absenteeism days
included missed work for all reasons, including illness, car-
ing for family members, and vacation. We included all rea-
sons for missed work because some employers operated with
a paid time off (PTO) policy that does not differentiate be-
tween reasons for missed work. We estimated the cost of a
missed workday based on the average daily wage for typi-
cal workers. For absenteeism days, the cost to an employer
for a missed day of work equaled that woman’s daily wage.
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For disability, the cost to the employer was set at 70% of the
woman’s daily wage because disability wages for employ-
ers in the database were generally paid at 70% of normal
wages. We estimated a woman’s average daily wage at $344
based on previous work with similar large companies like
those who contributed data to the HPM database.21 In a sen-
sitivity analysis, we computed results of absenteeism and
disability losses based on a $193.20 daily wage rate, based
on national daily wage and benefits estimates from the Bu-
reau of Labor Statistics for all U.S. companies in 2002.21
Observation period
Our primary analysis is based on the sample of patients with
at least 2 years of enrollment in their companies’ medical plans.
We divided medical expenditures into baseline and operative-
related expenditures for the analysis of patients with 2 years of
data (Fig. 1). We constructed the time period so that there was
a baseline year of observation (366 days) and a year of obser-
vation (366 days) after surgery to include the surgery and any
preoperative payments. Payments for claims originating dur-
ing the operative observation period were then divided into
preoperative, perioperative, and postoperative payments. Peri-
operative medical payments were payments made for claims
for services received at the time of the surgical procedure. For
outpatient procedures, this included payments for all claims on
the day of the surgery. For inpatient procedures, perioperative
payments included all payments for claims associated with the
inpatient stay for the surgical treatment. Preoperative payments
included all claims for medical services received during the 14
days prior to surgery. Baseline medical payments included all
payments for claims originating in the year before the start of
the preoperative observation period. The postoperative obser-
vation period began the day after discharge (or day after sur-
gery if outpatient surgery) and continued for a year after the
start of the preoperative period.
For women without surgical UF treatment, their operative
year began on the date of their earliest observed diagnosis
for UF (defined as a diagnosis without any other UF diag-
noses in the previous 365 days), and their baseline period
was the year prior to diagnosis. This diagnosis date should
be interpreted as the date the woman began an episode of
nonsurgical treatment for UF for women who we do not ob-
serve receiving surgical treatment for UF. We were able to
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TABLE 1. DESCRIPTION OF PROCEDURES RECEIVED BY PATIENTS IN EACH GROUP
Number of Perioperative
Procedure CPT-4 codes patients cost per patienta
Hysterectomy
Total abdominal 58150, 58152, 14,271 $9,881
58200





Laparoscopy 58550, 58552, 1,958 $9,010
58553, 58554,
56308
Subtotal hysterectomy 58180 607 $8,962
Other More than 1 151 $7,554
hysterectomy code
Radical 58210 31.b $16,312
Total: Hysterectomy 19,629 $9,594
Myomectomy
Abdominal 58140, 58146 1,588 $8,971
Vaginal 58145 92 $6,553
Laparoscopy 58545, 58546 44 $11,602
Other More than 1 19 $7,126
myomectomy code
Total: Myomectomy 1,743 $8,890
Endometrial ablation 56356, 58353, 1,115 $4,110
58561, and/or 58563
Uterine artery embolization (UAE)c 36247, 37204, 373 $10,696
and/or 52250
aAverage perioperative costs are not weighted or regression adjusted.
b12 of the 31 radical hysterectomy patients had diagnosis codes for cervical cancer (ICD-9-CM 180.0–180.9, 233.1) during the
year before surgery or at the time of the surgery (11 patients had cervical cancer codes as part of an inpatient stay). We have in-
cluded these patients, as some women with UF will have cervical cancer. The average cost of a hysterectomy decreased to $9,584
when the 31 patients with radical hysterectomy were excluded. This is $10 less than the average cost for all hysterectomy.
cOnly claims with both the uterine artery embolization CPT-4 codes and uterine fibroid diagnosis codes (ICD-9-CM diagno-
sis codes: 218.0–218.9 or 654.10–654.14) are included. For the other procedures, the patient must have a claim with the CPT-4
procedure code and meet the conditions for inclusion in the sample (they may or may not have a UF diagnosis on the claim with
the CPT-4 procedure code). Patients with codes from multiple procedure types (i.e., myomectomy and endometrial ablation)
could not be classified and are excluded from all analyses (55 patients).
observe all of these women for at least 1 year after the episode
began and 23% of them for 3 or more years.
We divided missed workdays before and after surgery in
a similar fashion to our analysis of medical costs by con-
structing a baseline year prior to the preoperative period and
an operative year that began with the preoperative period.
We used a different definition for preoperative and periop-
erative payments because the absenteeism and disability
data provided limited information on the reason for missed
work and because disability episodes typically lasted for a
month. We defined a preoperative and perioperative period
that encompassed the time 14 days prior to surgery through
28 days after surgery. We counted all absenteeism days dur-
ing this period and all disability episodes that began during
this time window as part of the preoperative and perioper-
ative costs. Postoperative missed days included all days
missed after the first 28 days after surgery for a year after
the start of the operative observation period.
To provide context for our cost analysis, we also observed
a subsample of patients with medical plan enrollment for 3
years before and 3 years after surgery. The purpose of the 6-
year analysis was to provide a broader picture of how the
cost history differs between surgically and nonsurgically
treated UF patients. In particular, we were interested in ob-
serving how costs in the first year after diagnosis for non-
surgical patients compared with their costs in subsequent
years. If peak medical expenditures occurred during the year
after diagnosis for women who were not treated surgically,
this would suggest that the year after diagnosis is the rele-
vant year to observe for nonsurgical patients when measur-
ing the costs of nonsurgical treatment. For the 6-year analy-
sis, we calculated the average annual medical expenditures
each year. Year 0 was defined as the year beginning on the
preoperative date (i.e., 14 days prior to surgery) and is the
same as the operative year in the 2-year analysis (Fig. 2).
Potentially confounding factors
We applied statistical techniques to control for potential
confounders that may impact observed costs. In everyday
clinical practice, outside the confines of a randomized clini-
cal trial, patients and their doctors will not choose a surgi-
cal procedure for UF (or any other type of treatment) ran-
domly.22 Factors involved in making such decisions include
the desire to preserve the woman’s childbearing ability; the
size, rate of growth, and location in the uterus of the fibroid;
the amount of bleeding or pain; the importance of avoiding
lengthy hospital stays; and other clinical or personal prefer-
ences that influence treatment choices. Factors that affect
treatment choices, but are not fundamentally part of the clin-
ical pathway, may potentially confound the care of patients
and cost estimates for each treatment.
Confounding variables can affect treatment in several
ways. For example, patients undergoing a hysterectomy
may be older and thus have higher expenditures than
younger women, regardless of the presentation of UF for
those patients. Thus, to estimate costs for hysterectomy
treatment compared with myomectomy, one would statis-
tically adjust for the fact that older women are more likely
to be treated with a hysterectomy. This adjustment would,
in turn, lower overall hysterectomy costs relative to other
treatments.
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FIG. 1. Observation period used in the 2-year medical care cost and absenteeism/disability analyses.
Because we relied on medical claims data for our analy-
ses, we could not directly observe clinical or motivational
variables that could potentially confound our analyses. We
did, however, have access to demographic information and
medical utilization patterns of patients during the baseline
period, which may be related to treatment choices. We, there-
fore, constructed measures of general health status, condi-
tions associated with UF, and the use of medical care ser-
vices and outpatient pharmaceuticals in the baseline year,
which could be used as control variables. We report these
patient characteristics for each study group and use them in
statistical analyses that attempt to balance the characteristics
of patients across groups. The next sections describe the pa-
tient characteristics we collected and the statistical methods
used to adjust for potential confounding.
Patient characteristics
We recorded the age of the patient on the day of the sur-
gery (or at diagnosis for women without surgical treatment).
Hysterectomy rates are known to vary by age, with the high-
est rates among women aged 40–44.8 We measured the lo-
cation of the patient’s residence, using the four regions iden-
tified by the U.S. Census Bureau. There are large regional
variations in hysterectomy rates; women in the South have
significantly higher hysterectomy rates than those in the
Northeast or West.8 Reasons for this regional variation in
procedure rates are not well understood but may be related
to variation in the underlying prevalence of disease, uncer-
tainties about the indications for hysterectomy, the avail-
ability of medical services and physicians, and patient pref-
erences.23 In addition to region, we categorized the type of
health plan providing coverage for women in the study as
health maintenance organization (HMO), FFS indemnity
plan, preferred provider organization (PPO), or point of ser-
vice (POS) plan. Plans with more managed care features,
such as HMOs, may have more administrative barriers to the
use of less common procedures, such as UAE and endome-
trial ablation, so we expected to find lower rates of these 
procedures for patients enrolled in plans with managed 
care features.
We measured the patient’s general overall health and
prognosis using the Charlson Comorbidity Index (CCI). The
CCI summarizes a patient’s risk of death or serious disabil-
ity in the coming year, based on whether diagnosis codes for
18 conditions were observed in the baseline period.24 CCI
values 6 indicate a high risk of death or major disability,
whereas values ranging from 2 to 6 indicated moderate risk
and values 2 indicate low risk. The CCI does not, however,
address mental illnesses in a complete manner, so we also
included a count of the number of psychiatric diagnosis
groups (PDGs) observed for each woman during the pre-
treatment period to measure complicating psychiatric ill-
nesses.25 There were 11 possible PDGs, which were aggre-
gated from ICD-9-CM diagnosis codes for mental health
problems. Examples included alcohol use disorders, other
substance use disorders, depression, bipolar disorder, post-
traumatic stress disorders (PTSD), and schizophrenia.
We also examined conditions that may be associated with
uterine fibroids. The list of conditions included pregnancy,
anemia, inflammatory diseases, endometriosis, noninflam-
matory disorders, pelvic pain, menstrual disorders, consti-
pation or gas, urinary problems, intestinal obstructions, and
others (i.e., disorders of the uterus not elsewhere classified,
genital prolapse, benign neoplasm of the uterus, and sep-
sis).2,3,17,26,27 Although these conditions may be taken into
account by the surgeon, their presence may indicate poten-
tially higher future expenditures regardless of the treatment
type selected by the patient and surgeon.
We also observed the use of medical services in the pre-
treatment year. These variables included measures of inpa-
tient admissions, emergency room visits, and the use of cer-
tain outpatient pharmaceuticals that may be prescribed to
control symptoms of UF. To measure pharmaceutical use,
we constructed an indicator to denote if any of the follow-
ing HTs were used during the pretreatment year: progestins
or oral contraceptives (OCs), gonadotropin-releasing hor-
mone agonists (GnRH-a), danazol, mifepristone, add-back
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FIG. 2. Observation period used in the 6-year medical cost analysis.
therapy (GnRH-a with a progestin or progestin and low-dose
estrogen, or the addition of a bisphosphonate), estrogen-pro-
gestin combinations that were not OCs, and single ingredi-
ent estrogens.6 We also included an indicator for whether
any prescriptions were filled for NSAIDs. The National Drug
Code (NDC) codes for each of these outpatient pharmaceu-
ticals were obtained using searches of the Drug RedBook™
Database. All the pharmaceutical measures were based on
outpatient drug claims, as inpatient pharmaceutical use data
were not available.
Statistical methods applied to adjust for potentially
confounding factors
We used regression analysis and propensity score weight-
ing to statistically adjust for differences among patient
groups for the sample with 2 years of enrollment. The re-
gression analysis adjusted for patient characteristics at base-
line (e.g., age, comorbidities present) that may be associated
with future costs. The analysis estimated the contribution of
each patient characteristic to costs, and this information was
used to predict adjusted costs for each treatment, holding
patient characteristics constant for each category of treat-
ment. The cost regressions were estimated using exponen-
tial models to account for the nonnormal distribution of med-
ical expenditure data.28 The dependent variable was annual
medical expenditures (or annual cost of missed workdays)
in the baseline or operative year. Independent variables in-
cluded indicators for each treatment group and whether the
data were from baseline or operative periods and patient
characteristics described in the previous section. We then es-
timated annual costs by using the exponential models to
compute mean predicted values from the sample.
The second analytical method used propensity score
weights to adjust for treatment choice effects. This is ac-
complished by first estimating the probability of receiving
each treatment, which is known in the health services and
epidemiology literatures as the patients’ “propensity score”.
The propensity score was estimated using a multinomial lo-
gistic regression model to estimate the probability that each
woman received a given treatment based on her age, type of
health plan, location, health status, and medical service uti-
lization in the pretreatment period. These predicted proba-
bilities were then used to create a weighting factor, described
by Rubin29 and by Imbens.30 We implemented weighted re-
gressions by multiplying the dependent variable (direct or
indirect cost) and independent variables (plan type, location,
demographic, utilization, and health status) by the weight-
ing variable (defined as the inverse of the predicted proba-
bility of selecting the treatment that was actually used). The
weighting variable helped to equalize these characteristics
across women in the surgical and nonsurgical groups before
costs were compared.
Once the propensity score weights were created, we eval-
uated the effectiveness of the weights by comparing the
weighted and unweighted means for all the variables that
were expected to influence procedure choice. If the weights
worked well, one would expect weighted means for patient
characteristics measures to be very similar (i.e., not signifi-
cantly different) for women in each surgical and nonsurgi-
cal treatment group.31 Similar mean values would increase
the confidence in subsequent direct and indirect cost com-
parisons because differences in the demographic, plan type,
location, health status, and utilization factors would have al-
ready been accounted for by the weighting prior to cost es-
timation. We then implemented weighted regression factors
by multiplying the dependent variable (direct or indirect
cost) and independent variables (plan type, location, demo-
graphic, utilization, and health status) by the weighting vari-
able (defined as the inverse of the predicted probability of
selecting the treatment that was actually used).
We present both unadjusted and regression adjusted
means in the tables. For the unadjusted means, we tested for
statistically significant differences between the medical care
costs and missed workdays for each group at 95% confidence
levels (CI) using the TTEST procedure in SAS (Cary, NC).
This procedure tests for the equality of the variances of each
pair of treatments using an F-test. Depending on the results
of the variance test, a p value was calculated using a t test
based on pooled variances (if variances were equal) or the
Satterthwaite method (if variances were not equal). For the
regression-adjusted results, the p values for the statistical
tests were obtained directly from the regression results. Be-
cause propensity score weighting did not substantively alter
our findings, we do not present weighted results in the ta-
bles and only briefly discuss the impact of weighting in the
Results section.
Results: Two-Year Sample
Characteristics of patients enrolled in health plans
We found 22,860 women with surgical treatments for UF
who were enrolled for at least 1 year prior to the preopera-
tive period and at least 1 year after the start of the preoper-
ative period. Most surgical patients received a hysterectomy
(85.9%), followed by myomectomy (7.6%), endometrial ab-
lation (4.9%), and UAE (1.6%). 14,214 women with a diag-
nosis of UF did not receive any surgical treatments. Table 1
shows the techniques used for each procedure based on CPT-
4 procedure codes. For myomectomy, the most common pro-
cedure was abdominal surgery, which included 91% of 
myomectomy patients (1,588 patients with abdominal my-
omectomy). For hysterectomy, total abdominal procedures
were most common (73% of hysterectomy patients), followed
by vaginal (13% of hysterectomy patients) and laparoscopic
(10% of hysterectomy patients) approaches. Table 1 also
shows the unadjusted mean perioperative costs for each pro-
cedure. Laparoscopic myomectomy cost on average $2,500
more than abdominal myomectomy and was undergone by
a small fraction of the sample (44 patients). Laparoscopic
hysterectomy patients had similar perioperative costs to to-
tal abdominal hysterectomy patients.
Table 2 shows the characteristics of patients included in
the study. Women who received a myomectomy tended to
be younger, and about one third were age 35. Hysterec-
tomy and UAE patients were older; only 3.9% of the hys-
terectomy patients and 5.6% of the UAE patients were 35.
Sample members were primarily enrolled in PPO and POS
plans. The largest portion of the sample resided in the
South, ranging from about 40% to almost 60% of the pa-
tients in each group. This reflected the distribution of con-
tributors to the MarketScan database, not necessarily the
location-related preferences for treatment. Similarly, more
sample members were found to have a first treatment in
CARLS ET AL.1124
2002 or 2003 because more employers contributed data to
MarketScan in those years.
Myomectomy patients were in the best overall health, as
measured by low CCI and PDG scores prior to surgery. Hys-
terectomy and endometrial ablation recipients had the high-
est CCI and PDG scores prior to treatment. Differences in
CCI scores were statistically significant among groups,
whereas differences in PDG scores were not. The most com-
mon other condition in all groups was menstruation disor-
ders, followed by pain diagnoses. Endometrial ablation pa-
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TABLE 2. SAMPLE OF WOMEN AGED 25–54 WITH UTERINE FIBROIDS WITH 2 YEARS OF
MEDICAL ENROLLMENT (PERCENT OF PATIENTS WITH EACH CHARACTERISTIC)a
Endometrial No surgical
Hysterectoy Myomectomy UAE ablation treatment
(n  19,629) (n  1,743) (n  373) (n  1,115) (n  14,214)
Number of women with 7,562 549 132 416 3,225
6 years of enrollment
Number of women contributing 497 93 25 25 372
HPM data
Demographics
Average age* 46.4 38.7 45.6 44.5 44.9
Age categories*
25–34 3.9% 33.8% 5.6% 10.0% 12.8%
35–44 41.7% 55.4% 38.6% 45.8% 38.9%
45–-54 54.4% 10.8% 55.8% 44.2% 48.4%
Census region*
Northeast 8.3% 15.2% 26.3% 17.8% 16.5%
North Central 24.4% 16.2% 23.6% 26.7% 21.8%
South 58.9% 56.9% 39.9% 44.2% 40.2%
West 8.3% 11.5% 10.2% 11.3% 21.5%
Missing/unknown 0.1% 0.2% 0.0% 0.0% 0.1%
Type of health plan*
FFS/Indemnity 15.4% 11.5% 18.5% 16.1% 14.4%
PPO 42.4% 35.0% 31.9% 40.9% 34.2%
POS/EPO 29.9% 35.0% 27.3% 27.4% 24.1%
HMO 8.4% 12.4% 15.5% 11.8% 21.7%
Capitated POS 3.9% 6.1% 6.7% 3.8% 5.6%
Missing/unknown 0.1% 0.0% 0.0% 0.1% 0.0%
Year of surgery (year of diagnosis 
if no surgery)*
2000 18.1% 20.7% 14.5% 13.3% 21.4%
2001 19.9% 18.6% 19.6% 18.7% 17.3%
2002 29.1% 25.8% 34.6% 30.3% 32.2%
2003 32.9% 34.9% 31.4% 37.8% 29.0%
Use of prescription drugs
in baseline period 
Hormone therapy* 33.0% 31.3% 31.6% 43.9% 25.9%
NSAID use* 29.9% 26.4% 27.3% 32.6% 25.3%
Health status in baseline period
Charlson Comorbidity Index 0.29 0.17 0.22 0.27 0.25
(CCI) (mean)*
Psychiatric diagnostic group 0.16 0.13 0.14 0.18 0.16
(PDG) (mean)
Other conditions in baseline period
Menstruation disorders* 53.4% 40.0% 51.7% 72.1% 24.9%
Pain* 31.4% 29.7% 22.3% 21.3% 12.9%
Other comorbidities*,b 21.3% 12.9% 11.0% 16.2% 6.1%
Anemias* 18.1% 14.8% 22.3% 22.1% 9.8%
Inflammatory diseases* 12.3% 17.7% 13.7% 12.5% 11.0%
Noninflammatory disorders* 17.1% 14.5% 9.4% 14.3% 8.7%
Endometriosis* 4.5% 5.9% 1.3% 3.7% 1.7%
Pregnancy* 1.8% 12.9% 2.7% 3.7% 9.1%
Urinary problems* 2.8% 2.0% 4.0% 1.6% 1.6%
Constipation or gas 1.1% 0.8% 0.3% 1.3% 1.0%
aWe also evaluated the percent of women with intestinal obstructions and peritonitis. Rates were trivially low, so these conditions are not
reported here.
bOther comorbidities include disorders of the uterus not elsewhere classified, genital prolapse, benign neoplasm of the ovary, and sepsis.
* Denotes variables with statistically significant differences between groups at 95% confidence levels.
tients were more likely than the other groups to have men-
struation disorder diagnoses (72%) during the baseline ob-
servation period. Hysterectomy patients were more likely to
have been diagnosed with pain prior to surgery than patients
who received other surgical interventions. Pregnancy dur-
ing the baseline period was more likely for myomectomy
(12.9%) and nonsurgical patients (9.1%) than for other
groups.
Medical care costs
Table 3 shows the unadjusted medical costs from baseline
through the end of the operative period for women with at
least 2 years of medical enrollment. Baseline annual costs
were similar for patients who received a surgical treatment
($4,418–$4,911). The only statistically significant differences
were between hysterectomy (more costly) and myomectomy
(p  0.0436), and between hysterectomy (more costly) and
UAE (p  0.0423). Baseline costs were significantly lower for
women without surgical treatment ($3,870) compared with
those who underwent any surgery.
Regression adjustment had a small impact on medical
costs in the baseline year (Table 3). Regression adjusted es-
timates of medical care costs in the baseline year were 5%
lower (hysterectomy) to 10% higher (UAE) than the unad-
justed mean estimates. After regression adjustment, baseline
cost differences between nonsurgical patients and patients
receiving each of the surgical treatments were statistically
significant. However, baseline cost differences between each
of the surgical treatments were not statistically significant.
Total unadjusted costs in the year of surgery (total oper-
ative costs) were highest for UAE at $16,430, followed by
hysterectomy ($15,180), myomectomy ($14,726), and endo-
metrial ablation ($12,096). Operative costs were significantly
lower for endometrial ablation compared with the other
three surgical treatments. Other operative cost differences
between surgical treatments were not statistically significant.
The cost increase from baseline was highest for UAE
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TABLE 3. MEDICAL CARE COSTS DURING 2-YEAR STUDY PERIOD (AVERAGE PAYMENTS FOR MEDICAL CARE PER PATIENT)
Total
Pre Peri Post operative
Baseline costs operative operative operative costs Cost
(1 year) costs costs costs (1 year)a increaseb
Not regression adjusted
Hysterectomyc
(n  19,629) $4,911M,U,N $625 $9,594M,E $4,961E $15,180E,N $10,269
Myomectomy
(n  1,743) $4,603H,N $579 $8,890H,U,E $5,257E $14,726E,N $10,123
Uterine artery embolization
(UAE)
(n  373) $4,418H,N $685 $10,696E,M $5,049E $16,430E,N $12,012
Endometrial ablation
(n  1,115) $4,793N $641 $4,110H,M,U $7,345H,M,U $12,096H,U,N $7,303
No surgical treatment
(n  14,214) $3,870H,M,E,U n.a.d n.a. n.a. $7,460H,M,U,E $3,590
Regression adjusted
Hysterectomy
(n  19,629) $4,665N $624 $9,562M,U,E $7,204M,U,E $17,390M,U,E,N $12,725
Myomectomy
(n  1,743) $4,610N $619 $8,969H,U,E $9,086H,U,E $18,674H,E,N $14,064
Uterine artery embolization
(UAE)
(n  373) $4,873N $670 $11,114H,M,E $8,850H,M,E $20,634H,E,N $15,761
Endometrial ablation
(n  1,115) $4,589N $629 $4,222H,M,U $8,168H,M,U $13,019H,M,U,N $8,430
No surgical treatment $3,812H,M,U,E n.a. n.a. $8,257 $8,257H,M,U,E $4,445
(n  14,214)
aTotal operative costs for patients without surgical treatment includes medical payments made during the year after first diagnosis for UF.
bCost increase is total costs in the operative year minus costs in the baseline year.
cThe hysterectomy cost estimates included the 31 patients with radical hysterectomy. The average cost for patients with radical hysterec-
tomy was $5,581 at baseline, $1,940 preoperative, $16,312 perioperative, and $16,653 postoperative. Excluding these patients did not signifi-
cantly impact results. The average cost for hysterectomy patients, excluding patients with a radical hysterectomy, was $4,910 at baseline, $623
preoperative, $9,583 perioperative, $4,943 postoperative. The total for the operative year was $15,149, which was an increase of $10,239 from
baseline.
dn.a., Not applicable; patients without surgical treatment do not have preoperative, perioperative, and postoperative costs.
H, Cost was significantly different from the cost incurred by hysterectomy patients.
M, Cost was significantly different from the cost incurred by myomectomy patients.
U, Cost was significantly different from the cost incurred by UAE patients.
E, Cost was significantly different from the cost incurred by endometrial ablation patients.
N, Cost was significantly different from the cost incurred by patients treated nonsurgically. Statistical significance was evaluated at 95%
confidence levels.
($12,012), followed by hysterectomy ($10,269), myomectomy
($10,123), and endometrial ablation ($7,303).
Regression adjustment increased costs by 8% for endo-
metrial ablation patients, 11% for nonsurgical patients, 15%
for hysterectomy patients, 26% for UAE patients, and 27%
for myomectomy patients. Without regression adjustment,
the most costly procedure was UAE, followed by hysterec-
tomy, myomectomy, and endometrial ablation. Regression
adjustment increased myomectomy costs above hysterec-
tomy costs; however, the cost difference between hysterec-
tomy and myomectomy patients was not statistically signif-
icant.
Average perioperative payments accounted for 60%–
65% of total operative costs for hysterectomy, myomec-
tomy, and UAE and only 48%–55% of total operative costs
once regression adjustment was applied. For endometrial
ablation, perioperative costs accounted for only 32%–34%
of total operative costs (with and without regression ad-
justment). Patients managing UF without surgical inter-
vention incurred medical costs of $7,460–$8,257 during the
year after diagnosis, an increase of $3,590–$4,445 from
baseline (range is based on unadjusted means and regres-
sion-adjusted estimates). Patients treated surgically sus-
tained significantly higher medical costs than those treated
without surgery.
We estimated a propensity score for the sample of women
with 2 years of medical claims data. These weights appeared
to help balance the groups of patients across treatments be-
cause the characteristics of patients in each group became
more similar when the weights were applied. However, the
weights had little impact on the cost estimates. Weighted es-
timates were within 10% of the unadjusted results reported
here and did not change the ordering of treatments in terms
of their medical care costs.
Characteristics of patients with absenteeism and 
disability information
We found 640 women with absenteeism and disability
data in the HPM database who were surgically treated for
UF and could be included in the analysis of missed work-
days. Of these, 77.7% received a hysterectomy, followed by
14.5% who received a myomectomy. UAE and endometrial
ablation each represented 3.9% of the surgically treated sam-
ple of patients. We also found 272 women who received non-
surgical treatment for UF and had data on absenteeism and
disability. The productivity data tended to include more
women in the younger age groups than the larger sample
with medical enrollment. An exception to this is the my-
omectomy group, which had a higher proportion of older
women. Women receiving endometrial ablation who had
productivity data appeared to be in poorer general health,
as measured by their CCI scores prior to treatment, com-
pared with women in the general sample. Women with pro-
ductivity data were more likely to be diagnosed with pain
than were women in the general sample. Menstruation dis-
orders were equally as likely to be diagnosed in women with
and without productivity data for the hysterectomy and my-
omectomy groups. Menstruation disorders were relatively
less likely to be diagnosed for women with productivity data
who were in the UAE, endometrial ablation, and nonsurgi-
cal treatment groups.
Missed workdays
Table 4 presents unadjusted average missed workdays
and associated costs due to absenteeism and short-term dis-
ability for the baseline and operative years. Baseline missed
workdays were very similar for myomectomy (35.5 days)
and nonsurgical patients (34.8 days) (p  0.8672). Patients in
the hysterectomy and UAE groups had somewhat higher
baseline missed workdays (44.0 days and 43.0 days, respec-
tively). The difference in missed days between hysterectomy
and UAE was not statistically significant (p  0.9003).
Differences in missed days were statistically significant for
comparisons between the hysterectomy group and other
groups. Missed workdays grew most for hysterectomy patients
(increase of 46.9 days) and myomectomy patients (increase of
38.8 days), followed by endometrial ablation patients (increase
of 19.5 days). Growth in missed days was relatively small for
UAE patients, at 7.4 days on average (17% of baseline). Patients
without surgical treatment had only 3.1 additional missed work-
days in the year after diagnosis compared with baseline. Missed
days during the preoperative and perioperative periods ac-
counted for about half of missed days during the operative ob-
servation period for hysterectomy and myomectomy patients,
whereas for UAE patients, preoperative and perioperative costs
accounted for 20% of costs during the operative period.
Missed workdays in the year after surgery cost employ-
ers $14,045–$25,008 on average for hysterectomy patients,
followed by $11,572–$20,924 for myomectomy patients,
$8,796–$15,662 for UAE patients, and $8,119–$14,456 for en-
dometrial ablation patients. In terms of missed workdays
due to absenteeism and short-term disability, surgical pa-
tients cost employers from about $5,000 (UAE) to $15,000
(hysterectomy) more than nonsurgical patients.
Regression adjustment had a small effect on estimates of
missed workdays. Regression adjustment increased or de-
creased missed workdays by 1–2 days (Table 4). We did not
estimate weights for the subsample of women who had ab-
senteeism and short-term disability data because there were
too few patients in that subsample to reliably estimate a
probability model. We explored whether to use the weights
derived from the sample of women with medical claims data
for our productivity studies and decided against it. The
weights exacerbated differences among groups because
women with productivity data were a nonrandom segment
of the total sample of women and the productivity data only
included employees, not dependents.
Results: Six-Year Sample
Patient characteristics
We found 8,659 women with surgical treatments for UF
in the CCAE database who were continuously enrolled for
3 years prior to the preoperative period and 3 years after. Of
these, 87.3% received a hysterectomy, followed by myomec-
tomy (6.3%), endometrial ablation (4.8%), and UAE (1.5%).
We also found 3,225 women with UF diagnoses who did not
receive surgical treatments and were enrolled 3 years before
and after their diagnosis.
Medical care costs
Figure 3 depicts how annual medical expenditures
changed over time for the sample of women with 6 years of
COST OF SURGICAL TREATMENT FOR UTERINE FIBROIDS 1127
enrollment in the data. Three years before surgery, average
annual expenditures for patients who eventually received
surgery ranged from $1,732 (UAE) to $3,211 (endometrial ab-
lation). Cost differences between surgical treatments were
statistically significant, except for myomectomy and UAE
costs (p  0.1558). Patients without surgical treatment had
similar medical care costs as hysterectomy patients ($2,595
for hysterectomy and $2,642 for no surgery patients) (p 
0.6840) 3 years prior to the operative year. During the years
prior to surgery, patients who were eventually treated with
hysterectomy, myomectomy, or endometrial ablation and
those treated nonsurgically experienced similar medical care
cost growth. Patients who eventually received UAE had a
much higher medical care cost growth prior to surgery (i.e.,
they had a steeper cost line slope). Patients who were not
treated surgically had the lowest growth in costs in the years
prior to diagnosis (i.e., their cost line slope was flatter than
the slopes of the other groups).
In the year of surgery or diagnosis (year 0), medical ex-
penditures by each group were significantly different, except
for UAE and hysterectomy patients (p  0.5559), UAE and
myomectomy patients (p  0.1097), and myomectomy and
endometrial ablation patients (p  0.1005). All groups expe-
rienced a large decrease in medical care costs in the period
following surgery or diagnosis. Hysterectomy, myomec-
tomy, and UAE patients experienced similar cost decreases
(62%–66%). Endometrial ablation patients experienced a
more moderate cost decrease of 44%. On average, nonsurgi-
cal patients experienced a cost decrease of 23% between 1
and 2 years after diagnosis. Two years after the operative
year (i.e., 3 years after surgery), medical care costs between
groups were not significantly different, except in the case of
hysterectomy and nonsurgical patients (p  0.0066).
Discussion
The objective of this study was to estimate the direct and
indirect costs of surgical treatments for UF. The total unad-
justed cost for hysterectomy patients during the operative
period was $29,225–$40,188 (obtained by adding unadjusted
average medical care costs equaling $15,180 to the range 
of unadjusted indirect costs, $14,045–$25,008). For these 
patients, there was an increase in their costs totaling
$16,423–$21,226 from baseline. Total unadjusted costs were
slightly lower for myomectomy patients ($26,478–$35,650)
during the operative period. Myomectomy patients experi-
enced a cost increase of $15,370–$19,464 from baseline. 
Despite the high perioperative medical cost of UAE, total 
unadjusted costs for UAE patients in the operative year 
were similar to costs for myomectomy, ranging from
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TABLE 4. AVERAGE ABSENTEEISM AND DISABILITY DAYS PER PERSON AND ESTIMATED COSTS DURING 2-YEAR STUDY PERIOD
Baseline Preoperative and Total operative
(1 year) perioperative Postoperative (1 year) Cost increasea
Not regression adjusted
Hysterectomy 44.0 daysM,E,N 41.5 daysU,E 49.4 daysM 90.9 daysM,U,E,N 46.9 days
(n  497) ($7,891–$14,051)b ($5,907–$10,518) ($8,138–$14,490) ($14,045–$25,008) ($6,154–$10,957)
Myomectomy 35.5H 38.1U,E 36.2 74.3H,U,E,N 38.8
(n  93) ($6,505–$11,583) ($5,409–$9,775) ($6,262–$11,149) ($11,752–$20,924) ($5,247–$9,341)
UAE 43.0 10.8H,M 39.5 50.4H,M 7.4
(n  25) ($7,631–$13,587) ($1,838–$3,273) ($6,958–$12,389) ($8,796–$15,662) ($1,165- $2,075)
Endometrial ablation 28.4H 9.1H,M 38.8 47.9H,M 19.5
(n  25) ($5,445–$9,695) ($1,570–$2,795) ($6,549–$11,661) ($8,119–$14,456) ($2,674–$4,761)
No surgical treatment 34.8H n.a.c n.a. 37.9H,M 3.1
(n  372) ($6,322–$11,239) ($6,670–$11,876) ($248–$637)
Regression Adjusted
Hysterectomy 43.0M,E,N 39.8U,E 52.2M 92.0M,U,E,N 49.0
(n  497) ($7,722-$13,750) ($5,672–$10,100) ($8,497–$15,129) ($14,169–$25,229) ($6,447–$11,479)
Myomectomy 34.8H 38.8U,E 34.0H 72.8H,E,N 38.0
(n  93) ($6,387–$11,373) ($5,566–$9,911) ($5,966–$10,622) ($11,532–$20,533) ($5,145–$9,160)
UAE 42.6H 11.5H,M 37.4 48.9H,M 6.3
(n  25) ($7,657–$13,633) ($2,025–$3,605) ($5,646–$11,834) ($8,671–$15, 439) ($1,014–$1,806)
Endometrial ablation 28.0H,M 9.6H,M 35.7 45.3H,M 17.3
(n  25) ($5,375–$9,570) ($1,640–$2,921) ($6,062–$10,795) ($7,702 -$13,716) ($2,327–$4,146)
No surgical treatment 35.2H,M n.a. n.a. 38.1H,M 2.9
(n  372) ($6,419–$11,427) ($6,735–$11,992) ($316–$565)
aCost increase is total operative costs minus baseline costs.
bThe lower bound of the range of costs is based on a value of $193.20/per day for absenteeism days and $135.24 for disability days. The
value of a disability day is 70% of the value of an absent day because disability programs typically pay 70% of wages. The upper bound is 
calculated in a similar way, based on a value of $344 per day.
cn.a., Not applicable. Patients without surgical treatment do not have pre-, peri-, and post-operative costs.
H, Cost was significantly different from the cost incurred by hysterectomy patients.
M, Cost was significantly different from the cost incurred by myomectomy patients.
U, Cost was significantly different from the cost incurred by UAE patients.
E, Cost was significantly different from the cost incurred by endometrial ablation patients.
N, Cost was significantly different from the cost incurred by patients treated nonsurgically. Statistical significance was evaluated at 95%
confidence levels.
$25,226–$32,092. Total costs of UAE patients increased by
$13,177–$14,087 from baseline. Patients who received endo-
metrial ablation experienced the lowest unadjusted medical
and absenteeism costs ($20,215–$26,552) in the operative
year. Patients who received endometrial ablation experi-
enced a total increase in costs of $9,977–$12,064. Finally, pa-
tients treated without surgery experienced a total cost in-
crease of $3,948–$4,227 from the baseline year.
Even though regression adjustment increased medical
costs for myomectomy patients more so than for hysterec-
tomy patients, total costs (indirect plus direct costs) for hys-
terectomy were still higher for hysterectomy patients largely
due to their higher indirect costs. Regression adjusted direct
and indirect operative costs for myomectomy patients were
$30,206–$39,207 compared with $31,559–$42,619 for hys-
terectomy patients. 
We found that whereas healthcare costs accounted for a
portion of total costs (in most cases, the largest portion), in-
direct costs due to missed workdays were also significant.
Direct costs for medical care accounted for 38% (hysterec-
tomy) to 70% (UAE) of total costs in the operative year, de-
pending on the treatment, value assigned to a missed work-
day, and use of regression adjustment.
Our 6-year analysis suggests that 3 years prior to surgery
or diagnosis, patients in the two largest groups, hysterec-
tomy and nonsurgical treatment, had almost identical total
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FIG. 3. Trends in medical care costs 3 years before and after index date includes only patients with 6 years of data.
costs and thus likely had a similar disease burden. Over the
next 3 years, costs diverged as costs increased more for pa-
tients who were eventually treated with hysterectomy. Six
years later, average costs for nonsurgical patients were about
$1,000 more than for hysterectomy patients. We cannot con-
clude, however, that subsequent lower costs for hysterec-
tomy patients are due to lower symptom relief for nonsur-
gical patients; nonsurgical patients were also more likely to
have a pregnancy after the UF diagnosis, which would have
increased their costs. 
The spike in costs in the year following diagnosis of UF
for the nonsurgical group (observed in the 6-year analysis)
suggests that that year represents the peak period for med-
ical treatment of the condition. Thus, we conclude that the
year following diagnosis is a relevant time period for mea-
suring the treatment costs for patients treated nonsurgically
for UF.
UAE patients had the lowest costs at the start of the 6-year
period, although at 3 years after surgery, they had similar
cost outcomes as myomectomy patients, suggesting that
UAE was similarly effective at least 3 years after surgery.
Three years prior to surgery, endometrial ablation patients
had the highest costs, suggesting that endometrial ablation
patients tend to have more complicated (or at least more
costly) clinical presentations at the outset. Costs in the year
beginning with surgery were lower for endometrial ablation
patients than for the other surgical treatments, but those costs
increase again after 2 years postsurgery, suggesting that
symptoms may have recurred for some endometrial ablation
patients. There was insufficient evidence to draw this con-
clusion, however, because the costs incurred by UAE pa-
tients were not significantly different from those of the other
groups because of the large variance in medical expenditures
by the UAE sample. A larger sample of patients and addi-
tional information, such as patient histories, are needed to
understand long-term cost implications of UAE treatment.
Most of our cost estimates (i.e., those for hysterectomy and
UAE) were greater than observed in previously published
studies, but some were consistent with those findings (i.e.,
our estimate for myomectomy was within the same range as
reported in previous studies). The review by Mauskopf 
et al.11 found short-term treatment cost estimates of
$5,012–$7,645 for hysterectomy, $5,425–$11,839 for myomec-
tomy, and $5,425–$7,645 for UAE (in 2004 dollars). When we
deflated our peri-operative medical cost estimates using the
CPI so that our estimates and those in previous studies re-
lated to the same base year, our cost estimates were $9,280
for hysterectomy, $8,599 for myomectomy, and $10,345 for
UAE.
There are several possible reasons why our estimates may
vary from previous estimates. Most of the previous studies
used an estimated cost/charge ratio to estimate treatment
cost. In contrast, we used actual paid claims to calculate ex-
penditures. All of the sample members in our study had em-
ployer-sponsored insurance; this was not the case in previ-
ous studies. Next, the site of care differed across studies. We
included inpatient and outpatient procedures from a variety
of settings, whereas other studies focused on patients from
a single hospital.12,13 In addition, all the previous studies
used data from the 1990s; our data were for the period
1999–2004. Technical advances in particular procedures can
alter costs over time. For example, an increased use of less
invasive myomectomy procedures could explain the lower
costs for myomectomy found in this study.
It is important to recognize that our results apply to the
particular mix of patients who received each treatment and
the mix of procedures used during our study. We described
characteristics of patients in each group to better under-
stand how those patients may be alike or different from
one another, but we lacked important clinical information,
such as the size, location, and rate of growth of the fibroid.
In the future, costs for traditional therapies (hysterectomy
and myomectomy) may decrease as less invasive tech-
niques for these therapies become more widespread. Av-
erage costs could increase for hysterectomy, however, if
patients with milder cases shift into the alternative treat-
ments, leaving mostly severe cases being treated with hys-
terectomy.
We may have underestimated the cost of surgical treat-
ment, especially for open procedures, which may include
some hysterectomy and myomectomy patients. For example,
patients with anemia who plan to undergo open procedures
must undergo more aggressive treatment for anemia prior
to surgery than patients who do not have open surgery.
These patients may take a drug, such as Lupron (Tap Phar-
maceuticals, Deerfield, IL), for 3–6 months prior to surgery
to more aggressively treat the anemia. These costs were in-
cluded in our baseline cost estimates, although they can be
thought of as part of the treatment costs.
In addition, we were not able to measure certain outcomes
using administrative data. For example, our analysis did not
account for presenteeism or the reduced productivity at
work that may be caused by pain and other symptoms of UF
and its treatment. We were also unable to include losses re-
sulting from the diminished capacity to perform nonwork
activities of daily living, such as household chores or leisure
activities. We also did not have access to other potentially
relevant information, such as education and type of job,
which could be related to treatment choice and use of ab-
sence and disability programs.
We were unable to account for the impact of UF or its treat-
ment on turnover (movement from employer to employer or
from employment to unemployment status). Moreover, the
sample of women with absenteeism and disability data was
small, particularly for those who received endometrial abla-
tion or UAE, so these estimates could have been influenced
by unusual cases. Also, we did not measure satisfaction with
care or other nonfinancial metrics that affect the utility of
each treatment choice. Thus, we conducted a cost-burden
analysis not a cost-effectiveness analysis.
Conclusions
Our study advances the literature by reporting on cost out-
comes related to the treatment of UF for 1–3 years after sur-
gical treatments. It should be noted, however, that some of
the follow-up costs associated with surgical choice may not
be realized until several years after treatment. Our results
for the sample with 6 years of data should be interpreted
with caution because some of the groups were small (espe-
cially the UAE group).
Future work may focus on estimating costs separately for
each type of procedure. For example, there are various pro-
cedures for myomectomy (abdominal, vaginal, hystero-
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scopic, laparoscopic), and differences in costs among these
procedures can be investigated. Medical claims data can dif-
ferentiate among some of these procedures (laparoscopic)
but not others (hysteroscopic).
We found that the total costs of surgical treatment for UF
were high. Total costs for hysterectomy and myomectomy
patients were similar, followed by UAE and endometrial ab-
lation. Costs were primarily linked to medical care, but pro-
ductivity-related costs were not trivial and differed among
treatment options. Indirect costs varied between surgical
treatments by a few hundred dollars (UAE and endometrial
ablation) to several thousand dollars (between hysterectomy
and UAE or endometrial ablation). Given the high costs of
care for UF patients, new cost-effective treatments that bet-
ter address the symptoms of the disease would be highly
valued.
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